J. Lo joins Sanofi for pertussis awareness ads

Share this article:
J. Lo joins Sanofi for pertussis awareness ads
J. Lo joins Sanofi for pertussis awareness ads
Sanofi Pasteur and the March of Dimes have recruited Jennifer Lopez to serve as the face of a whooping cough awareness campaign.

The campaign, dubbed “Sounds of pertussis,” includes TV and radio PSAs in English and Spanish urging new and expectant parents to make sure that they get vaccinated against pertussis, better known as whooping cough.

In the TV spot, Lopez sits at a sound board, listening to a loop of children coughing, and says: “Pertussis is most often spread by parents, and it's potentially fatal to infants. Even when babies themselves are vaccinated, they're not protected until after three or four doses. So, do what I did. Help protect your baby by protecting yourself. Ask your healthcare provider about the adult pertussis vaccine, ‘cause what would you do if your baby caught this from you?”

Sanofi and the March of Dimes cited a 100% increase in US cases of pertussis between 2000-2003 and 2004-2007, and said Hispanic babies may be at greater risk of contracting the disease and dying from it. In addition to Spanish-language PSAs, the campaign also includes a four-part “radio novella” that will air on Spanish-language radio stations throughout the country.

The campaign also includes educational brochures along with recorded telephone calls and emails featuring Lopez.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union